Flucelvax Tetra

RSS

Withdrawn

This medicine's authorisation has been withdrawn

influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
MedicineHumanWithdrawn

Icelandic is available via eTranslation, the European Commission's machine translation service.

Translate to Icelandic | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 23 February 2026, the European Commission withdrew the marketing authorisation for Flucelvax Tetra (influenza vaccine (surface antigen, inactivated, prepared in cell cultures)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Seqirus Netherlands B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Flucelvax Tetra was granted marketing authorisation in the EU on 12 December 2018. The authorised indication was prophylaxis of influenza in adults and children from 6 months of age.

The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2023.

български (BG) (156.84 KB - PDF)

Skoða

español (ES) (130.82 KB - PDF)

Skoða

čeština (CS) (164.86 KB - PDF)

Skoða

dansk (DA) (130.45 KB - PDF)

Skoða

Deutsch (DE) (135.21 KB - PDF)

Skoða

eesti (ET) (128.62 KB - PDF)

Skoða

ελληνικά (EL) (160.77 KB - PDF)

Skoða

français (FR) (132.36 KB - PDF)

Skoða

hrvatski (HR) (164.99 KB - PDF)

Skoða

italiano (IT) (129.88 KB - PDF)

Skoða

latviešu (LV) (163.16 KB - PDF)

Skoða

lietuvių (LT) (155.35 KB - PDF)

Skoða

magyar (HU) (165.45 KB - PDF)

Skoða

Malti (MT) (164.08 KB - PDF)

Skoða

Nederlands (NL) (131.26 KB - PDF)

Skoða

polski (PL) (158.17 KB - PDF)

Skoða

português (PT) (131.6 KB - PDF)

Skoða

română (RO) (163.7 KB - PDF)

Skoða

slovenčina (SK) (154.84 KB - PDF)

Skoða

slovenščina (SL) (153.21 KB - PDF)

Skoða

suomi (FI) (129.09 KB - PDF)

Skoða

svenska (SV) (129.5 KB - PDF)

Skoða

Product information

български (BG) (518.79 KB - PDF)

Skoða

español (ES) (443.32 KB - PDF)

Skoða

čeština (CS) (438.1 KB - PDF)

Skoða

dansk (DA) (434.21 KB - PDF)

Skoða

Deutsch (DE) (441.35 KB - PDF)

Skoða

eesti (ET) (408.64 KB - PDF)

Skoða

ελληνικά (EL) (510.75 KB - PDF)

Skoða

français (FR) (488.38 KB - PDF)

Skoða

hrvatski (HR) (470.98 KB - PDF)

Skoða

italiano (IT) (403.69 KB - PDF)

Skoða

latviešu (LV) (472.57 KB - PDF)

Skoða

lietuvių (LT) (467.27 KB - PDF)

Skoða

magyar (HU) (475.61 KB - PDF)

Skoða

Malti (MT) (507.08 KB - PDF)

Skoða

Nederlands (NL) (556.21 KB - PDF)

Skoða

polski (PL) (514.03 KB - PDF)

Skoða

português (PT) (438.63 KB - PDF)

Skoða

română (RO) (465.62 KB - PDF)

Skoða

slovenčina (SK) (480.83 KB - PDF)

Skoða

slovenščina (SL) (480.22 KB - PDF)

Skoða

suomi (FI) (454.48 KB - PDF)

Skoða

svenska (SV) (421.19 KB - PDF)

Skoða

Íslenska (IS) (414.98 KB - PDF)

Skoða

norsk (NO) (421.94 KB - PDF)

Skoða
Latest procedure affecting product information:II/0047
23/01/2025
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (91.58 KB - PDF)

Skoða

español (ES) (99.84 KB - PDF)

Skoða

čeština (CS) (88.71 KB - PDF)

Skoða

dansk (DA) (65.36 KB - PDF)

Skoða

Deutsch (DE) (64.84 KB - PDF)

Skoða

eesti (ET) (63.01 KB - PDF)

Skoða

ελληνικά (EL) (124.59 KB - PDF)

Skoða

français (FR) (63.14 KB - PDF)

Skoða

hrvatski (HR) (158.62 KB - PDF)

Skoða

italiano (IT) (63.34 KB - PDF)

Skoða

latviešu (LV) (87.47 KB - PDF)

Skoða

lietuvių (LT) (98.76 KB - PDF)

Skoða

magyar (HU) (87.76 KB - PDF)

Skoða

Malti (MT) (91.45 KB - PDF)

Skoða

Nederlands (NL) (73.97 KB - PDF)

Skoða

polski (PL) (90.49 KB - PDF)

Skoða

português (PT) (64.17 KB - PDF)

Skoða

română (RO) (87.53 KB - PDF)

Skoða

slovenčina (SK) (99.18 KB - PDF)

Skoða

slovenščina (SL) (80.7 KB - PDF)

Skoða

suomi (FI) (62.84 KB - PDF)

Skoða

svenska (SV) (83.78 KB - PDF)

Skoða

Íslenska (IS) (64.94 KB - PDF)

Skoða

norsk (NO) (63.99 KB - PDF)

Skoða

Product details

Name of medicine
Flucelvax Tetra
Active substance
A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022, CVR-167) A/Massachusetts/18/2022 (H3N2)-like strain (A/Sydney/1304/2022, wild type) B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type) B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type)
International non-proprietary name (INN) or common name
influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
Therapeutic area (MeSH)
Influenza, Human
Anatomical therapeutic chemical (ATC) code
J07BB02

Pharmacotherapeutic group

influenza, inactivated, split virus or surface antigen

Therapeutic indication

Prophylaxis of influenza in adults and children from 2 years of age.

Flucelvax Tetra should be used in accordance with official recommendations.

Authorisation details

EMA product number
EMEA/H/C/004814
Marketing authorisation holder
Seqirus Netherlands B.V.

Paasheuvelweg 28
1105 BJ Amsterdam
The Netherlands

Opinion adopted
18/10/2018
Marketing authorisation issued
12/12/2018
Withdrawal of marketing authorisation
23/02/2026
Revision
17

Assessment history

This page was last updated on

Share this page